Ergoteles LLC Tg Therapeutics, Inc. Transaction History

Ergoteles LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$15.48 - $35.0 $861,183 - $1.95 Million	55,632 New	55,632 $1.38 Million
Q4 2022 Feb 14, 2023	BUY	$5.01 - $11.83 $633,178 - $1.5 Million	126,383 New	126,383 $1.5 Million
Q2 2022 Aug 12, 2022	SELL	$3.74 - $10.66 $129,965 - $370,435	-34,750 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$7.81 - $20.45 $271,397 - $710,637	34,750 New	34,750 $330,000
Q4 2021 Feb 14, 2022	SELL	$15.2 - $35.51 $1.33 Million - $3.11 Million	-87,711 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$21.78 - $40.45 $1.91 Million - $3.55 Million	87,711 New	87,711 $2.92 Million
Q2 2021 Aug 12, 2021	SELL	$32.5 - $48.96 $1.3 Million - $1.96 Million	-40,100 Closed	0 $0
Q1 2021 May 12, 2021	BUY	$41.61 - $54.3 $1.67 Million - $2.18 Million	40,100 New	40,100 $1.93 Million

336

87.6M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.23B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.